RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
The purpose of this study is to compare a 2 immunosuppressant regimen for the treatment of
 relapsing or refractory necrotizing antineutrophil cytoplasmic antibody (ANCA) associated
 vasculitides.
The aim of this study is to compare the efficacy of rituximab versus infliximab in relapsing
 or refractory forms of ANCA+ vasculitides (Microscopic Polyangiitis, Wegener's granulomatosis
 and Churg-Strauss syndrome).
Inclusion Criteria:

 -  Systemic ANCA positive (+) vasculitides

 -  Relapsing or refractory vasculitides, resistant to corticosteroids and reference
 immunosuppressant therapies

 -  Age >18 years old

 -  Written informed consent

 Exclusion Criteria:

 -  Newly diagnosed patient

 -  Patient that had never received an immunosuppressant before to treat his/her
 vasculitis

 -  Malignancy

 -  Pregnancy